Sold as Frova. Every FDA application for this active ingredient: 1 branded and 5 generic.
As of Nov 15, 2026, FDA lists 6 applications for Frovatriptan Succinate (sold as Frova), first approved Nov 8, 2001, with 0 new uses approved and 0 published complete response letters.
| Frovatriptan Succinate | Part D | $1.9M | -13% | 2,036 |
| Frova | Part D | $144K | -62% | 25 |
| Nov 8, 2001 | FrovaNDA 21006 ยท New molecular entity | Endo Operations | 9 | Discontinued |
| Aug 28, 2014 | Frovatriptan SuccinateANDA 202931 | Pharmobedient | 2 | Discontinued |
| Mar 11, 2016 | Frovatriptan SuccinateANDA 204730 | Glenmark Pharms Ltd | 1 | Marketed |
| Nov 6, 2018 | Frovatriptan SuccinateANDA 211292 | Amneal Pharms Co | 1 | Marketed |
| Apr 6, 2022 | Frovatriptan SuccinateANDA 213891 | Renata | 0 | Marketed |
| Apr 16, 2025 | Frovatriptan SuccinateANDA 216998 | Leading | 0 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
